The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use | Agenda Bookshop Skip to content
Online orders placed from 19/12 onward will not arrive in time for Christmas.
Online orders placed from 19/12 onward will not arrive in time for Christmas.
A01=and Medicine
A01=Board on Health Sciences Policy
A01=Committee on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Replacement Therapy
A01=Engineering
A01=Health and Medicine Division
A01=National Academies of Sciences
Age Group_Uncategorized
Age Group_Uncategorized
Author_and Medicine
Author_Board on Health Sciences Policy
Author_Committee on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Replacement Therapy
Author_Engineering
Author_Health and Medicine Division
Author_National Academies of Sciences
automatic-update
B01=Donald R. Mattison
B01=Leigh Miles Jackson
B01=Ruth M. Parker
Category1=Non-Fiction
Category=MJT
COP=United States
Delivery_Delivery within 10-20 working days
Language_English
PA=Available
Price_€50 to €100
PS=Active
softlaunch

The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use

The U.S. Food and Drug Administration (FDA) has approved dozens of hormone therapy products for men and women, including estrogen, progesterone, testosterone, and related compounds. These products have been reviewed for safety and efficacy and are indicated for treatment of symptoms resulting from hormonal changes associated with menopause or other endocrine-based disorders. In recent decades, an increasing number of health care providers and patients have turned to custom-formulated, or compounded, drug preparations as an alternative to FDA-approved drug products for hormone-related health concerns. These compounded hormone preparations are often marketed as bioidentical or natural and are commonly referred to as compounded bioidentical hormone therapy (cBHT).

In light of the fast-growing popularity of cBHT preparations, the clinical utility of these compounded preparations is a substantial public health concern for various stakeholders, including medical practitioners, patients, health advocacy organizations, and federal and state public health agencies. This report examines the clinical utility and uses of cBHT drug preparations and reviews the available evidence that would support marketing claims of the safety and effectiveness of cBHT preparations. It also assesses whether the available evidence suggests that these preparations have clinical utility and safety profiles warranting their clinical use and identifies patient populations that might benefit from cBHT preparations in lieu of FDA-approved BHT.

Table of Contents
  • Front Matter
  • Summary
  • 1 Introduction
  • 2 An Overview of Compounding
  • 3 Regulatory Framework for Compounded Preparations
  • 4 Reproductive Steroid Hormones: Synthesis, Structure, and Biochemistry
  • 5 Compounded Bioidentical Hormone Preparations
  • 6 Bioavailability of Compounded Bioidentical Hormone Therapy Preparations
  • 7 The Safety and Effectiveness of Compounded Bioidentical Hormone Therapy
  • 8 The Use of Compounded Bioidentical Hormone Therapy
  • 9 Clinical Utility and Recommendations
  • Appendix A: Study Approach
  • Appendix B: Study Methods
  • Appendix C: Glossary
  • Appendix D: Biosketches
  • Appendix E: 503A and 503B Distribution Supplement
  • Appendix F: Compounded Bioidentical Hormone Therapy Formulations with a Single Active Ingredient
  • Appendix G: Compounded Bioidentical Hormone Therapy Formulations with Two or More Active Ingredients
  • Appendix H: Boxed Warnings on U.S. Food and Drug AdministrationApproved Estrogen and Testosterone Products
See more
Current price €75.04
Original price €78.99
Save 5%
A01=and MedicineA01=Board on Health Sciences PolicyA01=Committee on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Replacement TherapyA01=EngineeringA01=Health and Medicine DivisionA01=National Academies of SciencesAge Group_UncategorizedAuthor_and MedicineAuthor_Board on Health Sciences PolicyAuthor_Committee on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Replacement TherapyAuthor_EngineeringAuthor_Health and Medicine DivisionAuthor_National Academies of Sciencesautomatic-updateB01=Donald R. MattisonB01=Leigh Miles JacksonB01=Ruth M. ParkerCategory1=Non-FictionCategory=MJTCOP=United StatesDelivery_Delivery within 10-20 working daysLanguage_EnglishPA=AvailablePrice_€50 to €100PS=Activesoftlaunch
Delivery/Collection within 10-20 working days
Product Details
  • Dimensions: 152 x 229mm
  • Publication Date: 22 Oct 2020
  • Publisher: National Academies Press
  • Publication City/Country: United States
  • Language: English
  • ISBN13: 9780309677127

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept